Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Clinical characteristics of 64 pediatric XLH patients on burosumab treatmentCharacteristicsAllFemaleMale p n (%)64 (100)36 (56.3)28 (43.7)n.a.Age at diagnosis, years1.0 (0.06; 3.0)1.9 (0.2; 3.0)0.2 (0.0; 2.0) 0.016 Positive family history, n (%)10 (15.6)2 (5.6)8 (28.6) 0.012 Age at observation, years13.05 (10.39; 14.79)12.0 (10.5; 14.6)13.6 (10.3; 15.1)0.598Age at start of burosumab, years9.8 (7.6; 12.2)9.8 (8.0; 11.9)10.2 (8.4; 12.2)0.675Duration burosumab, years2.78 (1.36; 3.79)2.43 (1.29; 3.47)2.27 (1.21; 3.87)0.749Burosumab dosage, mg/kgd0.63 (0.36; 1.12)0.73 (0.48; 1.13)0.58 (0.31; 1.07)0.166Prior treatment active D/Pi, n (%)35 (54.7)22 (61.1)13 (46.6)0.460Prior treatment active D/Pi, years7.2 (4.6; 9.9)7.2 (4.2; 9.6)9.1 (3.3; 12.5)0.415Height, cm146.1 (131.2; 153.6)141.6 (130.2; 152.5)147.4 (130.3; 154.3)0.548Height, z-score− 1.92 (− 2.71; − 1.17) c− 1.95 (− 2.73; − 0.61) c− 1.98 (− 3.04; − 1.46) c0.325Weight, kg47.9 (32.2; 55.5)43.6 (32.5; 54.1)47.2 (29.0; 52.9)0.543Weight, z-score− 0.64 (− 1.50; 0.49) b− 0.78 (− 2.07; 0.35)− 0.91 (− 1.49; − 0.46) a0.855BMI, kg/m20.69 (18.06; 24.46)20.6 (17.6; 24.0)20.2 (18.1; 24.2)0.598BMI, z-score0.64 (0.005; 1.49) c0.53 (− 0.29; 1.48) a0.61 (0.06; 1.27) c0.481Overweight, n (%)8 (12.5)5 (13.9)3 (10.7)0.703Obesity, n (%)11 (17.2)6 (16.7)5 (17.9)0.900Self-report questionnaires, n (%)49 (76.6)29 (80.6)20 (71.4)0.393Proxy questionnairese, n (%)59 (92.2)34 (94.4)25 (85.7)0.446Both Proxy & Self-report, n (%)43 (67.2)27 (75.0)16 (57.1)0.131Data is presented as median (interquartile range) or n (%), p values were calculated using one sample Wilcoxon test, unpaired Mann-Whitney test and Chi-Pearson-Square test, as appropriate. a p < 0.05; b p < 0.01; c p < 0.001 versus healthy controls; d given every two weeks; Active D/Pi, active vitamin D and phosphate salts;e information provided by biological parents; BMI, body mass indexBold significance levels indicate a p value < 0.05
Source: Patient characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cross-sectional study.
Cross-sectional study
Examines a population at a particular point in time.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
In this cross-sectional analysis of a prospective binational observational study, we investigated HRQoL in 64 pediatric XLH patients (36 female) on burosumab treatment, using the KIDSCREEN-52 questionnaire and qualitative interviews.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Health-Related Quality of Life in Children with X-Linked Hypophosphatemia Treated with Burosumab: Real-World Data from a German-Swiss Study
Cross-sectional study · Calcified Tissue International · 2026
Original publication title
Health-Related Quality of Life in Children with X-Linked Hypophosphatemia Treated with Burosumab: Real-World Data from a German-Swiss Study
© The Author(s) 2026
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Burosumab is effective in improving rickets in children with X-linked hypophosphatemia (XLH). Predictors of health-related quality of life (HRQoL) in pediatric XLH patients treated with burosumab are unknown. In this cross-sectional analysis of a prospective binational observational study, we investigated HRQoL in 64 pediatric XLH patients (36 female) on burosumab treatment, using the KIDSCREEN-52 questionnaire and qualitative interviews. Associations between HRQoL and clinical findings were analysed using multiple regression and receiver operating characteristics (ROC) curve analyses. Median age at investigation and duration of burosumab treatment were 13.1 (IQR 10.4; 14.8) and 2.8 (IQR 1.4; 3.8) years, respectively; 54.7% of patients received secondary burosumab treatment following prior active vitamin D and phosphate.
Overall, HRQoL scores were comparable to national reference values. Caregivers rated Physical Well-Being, Moods & Emotions, and Bullying lower than the patients themselves. Burosumab dose was significantly associated with Physical Well-Being, Psychological Well-Being, and Self-Perception in self-report, and with total T-values and Physical Well-Being in proxy questionnaires. The duration of prior treatment with active vitamin D and phosphate was significantly associated with the dimension of Autonomy in self-report and proxy reports. A burosumab dosage above 0.6 mg/kg was associated with a good Physical Well-Being (above the mean of the general population) with a sensitivity and specificity of 75% and 70% in self-report, and 67% and 70% in proxy questionnaires, respectively.
In this real-world study, HRQoL in burosumab-treated children with XLH was comparable to that of the general population and associated with burosumab dosage.
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1007/s00223-026-01602-x.
Authors’ abstract
Burosumab is effective in improving rickets in children with X-linked hypophosphatemia (XLH). Predictors of health-related quality of life (HRQoL) in pediatric XLH patients treated with burosumab are unknown. In this cross-sectional analysis of a prospective binational observational study, we investigated HRQoL in 64 pediatric XLH patients (36 female) on burosumab treatment, using the KIDSCREEN-52 questionnaire and qualitative interviews. Associations between HRQoL and clinical findings were analysed using multiple regression and receiver operating characteristics (ROC) curve analyses. Median age at investigation and duration of burosumab treatment were 13.1 (IQR 10.4; 14.8) and 2.8 (IQR 1.4; 3.8) years, respectively; 54.7% of patients received secondary burosumab treatment following prior active vitamin D and phosphate.
Overall, HRQoL scores were comparable to national reference values. Caregivers rated Physical Well-Being, Moods & Emotions, and Bullying lower than the patients themselves. Burosumab dose was significantly associated with Physical Well-Being, Psychological Well-Being, and Self-Perception in self-report, and with total T-values and Physical Well-Being in proxy questionnaires. The duration of prior treatment with active vitamin D and phosphate was significantly associated with the dimension of Autonomy in self-report and proxy reports. A burosumab dosage above 0.6 mg/kg was associated with a good Physical Well-Being (above the mean of the general population) with a sensitivity and specificity of 75% and 70% in self-report, and 67% and 70% in proxy questionnaires, respectively.
In this real-world study, HRQoL in burosumab-treated children with XLH was comparable to that of the general population and associated with burosumab dosage.
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1007/s00223-026-01602-x.
Publication and source details
Original title: Health-Related Quality of Life in Children with X-Linked Hypophosphatemia Treated with Burosumab: Real-World Data from a German-Swiss Study
Ineke Böckmann; Martin Klein; Helena Mutze; Mirko Rehberg; Giuseppina Spartà; Katrina Evers; Karl Peter Schlingmann; Markus J. Kemper; Annette Richter-Unruh; Dorothee Schmidt; Olaf Hiort; Karina Grohmann-Held; Carmen Schröder; Ute Derichs; Clemens Freiberg; Marcus Weitz; Desiree Dunstheimer; Elmar Schmid; Ulrike John-Kroegel; Oliver Metzing; Sabine Heger; Norbert Jorch; Hagen Staude; Ludwig Patzer; Elke Wühl; Carl-Joachim Partsch; Angela Hübner; Michaela Marx; Christof Land; Norbert Albers; Jens Banzer; Inka Baus; Frauke Wilkening; Kristina Möller; Verena Wagner; Gabriele Krauch; Michaela Gessner; Alexandra Goischke; Maren Leifheit-Nestler; Miroslav Zivicnjak; Dirk Schnabel; Dieter Haffner
Calcified Tissue International · 2026
© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Medizinische Hochschule Hannover (MHH) (3118)Open Access funding enabled and organized by Projekt DEAL.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T21:40:41.160931+00:00
DOI: 10.1007/s00223-026-01602-x · PMC13582184